ArticleChemistry & biodiversity2026
In Silico, In Vitro, and In Vivo Evaluation of Woodfordia Fruticosa for Cardio Protection against Doxorubicin-Induced Cardiomyopathy.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the therapeutic potential of Woodfordia fruticosa, known for its cardioprotective properties, using in silico, in vitro, and in vivo methods. Fourier-transform infrared spectroscopy (FTIR) and gas chromatography-mass spectrometry (GC-MS) analyses were used to identify and characterize the bioactive compounds in W. fruticosa. Molecular docking with dock score assessed the binding affinities of hecogenin, β-sitosterol, and pulmatin. Antioxidant potential was evaluated using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and ferric reducing antioxidant power (FRAP) assays. In vivo experiments involved inducing cardiomyopathy in Wistar albino rats with doxorubicin (16 mg/kg, ip) and treating them with W. fruticosa flower extract at doses of 100, 200, and 400 mg/kg for 16 days. Molecular docking studies revealed that hecogenin, β-sitosterol, and pulmatin exhibited strong binding affinities against human protein kinase ZAK, with Dock scores of -12.07, -11.42, and -11.04, respectively, surpassing the standard drug ramipril (-9.32). FTIR and GC-MS confirmed the presence of key phytoconstituents, including β-sitosterol, hecogenin, ellagic acid, kaempferol, and 2-hydroxy-1,4-naphthoquinone (Lawsone). In vitro antioxidant assays demonstrated significant free radical scavenging activity comparable to ascorbic acid. In vivo studies in Wistar albino rats showed that W. fruticosa flower extract significantly (p < 0.001) improved electrocardiogram (ECG) parameters, and significantly (p < 0.001) reduced cardiac biomarkers, including creatine kinase myocardial band (CK-MB), lactate dehydrogenase (LDH), and cardiac troponin I, and mitigated histopathological damage in a dose-dependent manner caused by doxorubicin. The 400 mg/kg dose exhibited the most pronounced cardioprotective effects, normalizing ECG patterns, decreasing myocardial injury, and reducing fibrosis. W. fruticosa flower extract exhibited significant cardioprotective potential via the human protein kinase ZAK pathway against doxorubicin-induced cardiomyopathy through in silico, in vitro, and in vivo evaluations. These findings suggest W. fruticosa as a promising natural agent for cardiomyopathy management, warranting further studies to elucidate its mechanisms, optimize dosing, and validate long-term safety and efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.